Home › Products › Oncology › Ibrushil 140mg Capsule 30's
Ibrushil 140mg Capsule 30's
Salt Composition: IBRUTINIB
- Manufacturer: SHILPA MEDICARE LTD
- Pack Size: 30 CAPSULE(s) IN A BOTTLE
- Dosage Form: CAPSULE
- Strength: 140MG
- Prescription Required
- Storage: Store the capsules in the original packaging below 30°C Keep out of reach of children
₹6539.00₹8429.06
Inclusive of all taxes
Product Introduction
Ibrushil 140mg Capsule contains the active ingredient Ibrutinib. It is indicated for the treatment of blood cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL). These are malignancies of white blood cells called lymphocytes, which form part of the immune system. They differ in the location of cancer development, the type of lymphocytes involved, and certain other characteristics. Ibrushil 140mg Capsule is also used to treat chronic graft versus host disease (cGvHD) following failure of systemic therapy. In allogeneic stem cell transplantation, the patient receives stem cells from a donor. GvHD occurs when donor cells attack the patient's own cells as foreign material. Before starting an Ibrutinib Capsule, inform your physician if you have bleeding disorders, infection, liver disease, heart disease, or intolerance to certain sugars. This medication is not recommended for children and adolescents. It is important to inform your physician if you have recently undergone or are scheduled for any surgical procedure. Your physician may discontinue Ibrushil 140mg Capsule in relation to any planned surgical or medical procedure. Use effective contraception during treatment and for at least one month following the final dose. Avoid consuming grapefruit or oranges in any form during this treatment, as they may increase the blood concentration of the medication. Drink adequate fluid to prevent dehydration. Inform your physician if you experience diarrhoea that persists.
Uses
Ibrushil 140mg Capsule is used in the treatment of: Mantle cell lymphoma Chronic lymphocytic leukaemia (Blood cancer) Small lymphocytic lymphoma Waldenstromâs macroglobulinemia Chronic graft vs. host disease after failure of systemic therapy
How it works
The mechanism of action of Ibrushil 140mg Capsule involves blocking a specific protein called Bruton's tyrosine kinase (BTK) which plays a key role in the survival and growth of cancer cells. By inhibiting BTK, Ibrushil 140mg Capsule prevents the cancer cells from receiving the signals they need to grow and divide, leading to their eventual death.
How to Use
Consume this medicine at the same time each day. While taking Ibrushil 140mg Capsule, do not consume grapefruit or orange in any form during the treatment. Drink plenty of fluid to prevent dehydration.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious: Bleeding problems Infections Decrease in blood cell counts Heart problems High BP Secondary cancer Tumor lysis syndrome Severe allergic reactions Common: Nausea, vomiting, diarrhea Tiredness Muscle and bone pain Rash and bruising Mouth sores Pneumonia Fever, chills Breathlessness Constipation Dizziness Body pain Swollen ankles and feet Increased creatinine levels in blood Heavier periods and blood in urine Blurred vision Weakness and numbness
Expert Tips
Contact your doctor immediately if you experience bleeding, infection, shortness of breath, or chest discomfort. Report to your doctor if you have had a history of heart failure or hepatitis infection. It is not recommended to take this medicine before or after surgery as it causes a delay in wound healing. Discuss effective contraceptive options with your healthcare provider and use them during treatment and for a month after the last dose of Ibrushil 140mg .
References
- Janssen-Cilag International Ltd, Electronic Medicines Compendium (EMC), [Revised on Dec 2021] [Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.10040.pdf
- Janssen Biotech, Inc, US Food and Drug Administration, [Revised on May 2022] [ 18th March 2023], https://www.imbruvica.com/files/prescribing-information.pdf
- H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidsonâs Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
- Sapna Parmar, Khilna Patel, Javier Pinilla-Ibarz, Ibrutinib (Imbruvica): A Novel Targeted Therapy for Chronic Lymphocytic Leukemia, Drug Forecast, Published on July 2014; Accessed on 18th March 2023]; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103574/pdf/ptj3907483.pdf
Safety Advice
Pregnancy: unsafe This medicine can harm the unborn baby. Do not take Ibrushil 140mg Capsule unless your physician instructs you to take it. Inform your physician before starting this treatment if you are pregnant or think you might be pregnant.
Lungs: Consult your doctor Ibrushil 140mg capsule may cause interstitial lung disease. So if you have any respiratory disorder, inform your doctor before starting the treatment.
Breastfeeding: unsafe Do not breastfeed while you are under Ibrushil 140mg capsule and for at least one week after the last dose. Consult your physician for risks and benefits.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.